Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Condition: Non-small Cell Lung Cancer Interventions: Drug: Anlotinib Plus Docetaxel; Drug: Docetaxel Sponsor: First Affiliated Hospital of Guangxi Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | Hospitals | Non-Small Cell Lung Cancer | Taxotere